Categories: Wire Stories

Shanghai Pharmaceutical Co Ltd 2020: Financial & Strategic SWOT Analysis Review – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Shanghai Pharmaceutical Co Ltd (601607) – Financial and Strategic SWOT Analysis Review” swot analysis has been added to ResearchAndMarkets.com’s offering.

Shanghai Pharmaceutical Co Ltd (601607) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Shanghai Pharmaceutical Co Ltd (Shanghai Pharma) is a manufacturer, retailer, wholesaler, and distributor of healthcare products. The company carries out the researches, develops, produces, and sells pharmaceutical products for the treatment of HER2 positive advanced breast cancer, systemic anti-infection, and antineoplastic drug and immunomodulator. It also offers medicines for diseases and disorders of cardiovascular system, digestive and metabolism, neurological system, musculoskeletal system, and respiratory system. Shanghai Pharma also provides traditional Chinese medicines. It provides distribution and supply chain solutions to pharmaceutical manufacturers and dispensers; operates retail pharmacy stores; and provides consulting services, assets management and other services. The company operates through its subsidiaries in China. Shanghai Pharma is headquartered in Shanghai, China.

Key benefits of buying this profile include:

  • You get detailed information about the company and its operations to identify potential customers and suppliers.
  • Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Gain key insights into the company for academic or business research.

Key Topics Covered:

Section 1 – About the Company

  • Shanghai Pharmaceutical Co Ltd – Key Facts
  • Shanghai Pharmaceutical Co Ltd – Key Employees
  • Shanghai Pharmaceutical Co Ltd – Key Employee Biographies
  • Shanghai Pharmaceutical Co Ltd – Major Products and Services
  • Shanghai Pharmaceutical Co Ltd – History
  • Shanghai Pharmaceutical Co Ltd – Company Statement
  • Shanghai Pharmaceutical Co Ltd – Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Affiliate

Section 2 – Company Analysis

  • Company Overview
  • Shanghai Pharmaceutical Co Ltd – Business Description
  • Business Segment: Distribution and Supply Chain Solutions
  • Overview
  • Performance
  • Business Segment: Other Business Operations
  • Business Segment: Pharmaceutical Business
  • Business Segment: Pharmaceutical Retail
  • R&D Overview
  • Shanghai Pharmaceutical Co Ltd – Corporate Strategy
  • Shanghai Pharmaceutical Co Ltd – SWOT Analysis
  • SWOT Analysis – Overview
  • Shanghai Pharmaceutical Co Ltd – Strengths
  • Shanghai Pharmaceutical Co Ltd – Weaknesses
  • Shanghai Pharmaceutical Co Ltd – Opportunities
  • Shanghai Pharmaceutical Co Ltd – Threats
  • Shanghai Pharmaceutical Co Ltd – Key Competitors

Section 3 – Company Financial Ratios

  • Financial Ratios – Capital Market Ratios
  • Financial Ratios – Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios – Interim Ratios
  • Financial Ratios – Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

  • Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
  • Shanghai Pharmaceutical Co Ltd, Recent Deals Summary

Section 5 – Company’s Recent Developments

  • Sep 30, 2019: Shanghai Pharma Global Standard Stock Incentive Scheme to push innovation refiled for approval

Section 6 – Appendix

  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact Us
  • Disclaimer

Companies Mentioned

  • Sinochem Hebei Corp
  • Shenzhen Accord Pharmaceutical Co Ltd
  • Nanjing Pharmaceutical Co Ltd
  • Harbin Pharmaceutical Group Holding Co Ltd
  • Sihuan Pharmaceutical Co Ltd
  • Simcere Pharmaceutical Group
  • Tasly Pharmaceutical Group Co Ltd
  • Sihuan Pharmaceutical Holdings Group Ltd

For more information about this swot analysis visit https://www.researchandmarkets.com/r/fzuvy4

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Alex

Recent Posts

Cathay expands lifestyle offerings in Southeast Asia with Mitsui Mall Group partnership in Malaysia

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 24 March 2025 - Premium travel lifestyle…

2 hours ago

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

GUANGDONG, CHINA AND BAGSVÆRD, DENMARK - Media OutReach Newswire - 24 March 2025 - The…

3 hours ago

Contractor Sentiment Generally Positive as the Worst of Price Pressures Ease, According to Office Fit Out Vendors Across Asia Pacific

Six Greater China cities are ranked in the top 20 most expensive office fit out…

4 hours ago

SonicWall Partner Focus Drives Key Business Momentum in Transformational Year

SonicWall’s Wide-ranging Platform of Cybersecurity Solutions and Growth with Managed Security Services Providers (MSSPs) Underpin…

4 hours ago

Lenovo Hybrid AI Advantage with NVIDIA Boosts Business Productivity and Efficiency with New Scalable Agentic AI Solutions

New Lenovo agentic AI and hybrid AI factory platforms include NVIDIA Blackwell Ultra support and…

4 hours ago

CTF Life Introduces “GBA MediAccess” Outpatient Insurance Plan

Leverages CTF Group’s Diverse Conglomerate to Address Medical Needs of Families in the Guangdong–Hong Kong–Macau…

5 hours ago